Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trubion Finds Kindred Spirit in Facet For Co-Development And Commercialization

This article was originally published in The Pink Sheet Daily

Executive Summary

Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.
Advertisement

Related Content

Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid
Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid
Facet Rejects Biogen Again, Opens Up to Other Bids
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Fresh Off Tysabri Court Win, Biogen Idec Makes A Hostile Bid For Facet Biotech
Troubled Biotechs: Orexigen, Telik, Trubion
Scant Worry Over PDL Patent Challenges
Scant Worry Over PDL Patent Challenges

Topics

Advertisement
UsernamePublicRestriction

Register

PS069906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel